Skip to main content

Zycos Wins DNA-Delivery Patent

NEW YORK, Nov. 19 — Zycos, a Lexington, Mass., drug-development company, announced on Monday that it has been granted a patent on its microparticle DNA delivery method.


According to the company, the invention, called GENCAP, protects DNA from degradation in the body. The microparticles that protect the DNA are derived from a material also used in resorbable sutures, and Zycos has adapted the material to encapsulate and protect plasmid DNA vaccines.


This technique, according to the company, is superior to naked DNA vaccines in its ability to deliver antigen-coding DNA into relevant immune system cells and generate a robust B-cell and cytotoxic T-cell response.


The patent was granted on Oct. 30.


Zycos is also developing its own drug pipeline, focusing on treatments for cancers, infectious diseases and autoimmune disorders, and currently has one treatment for cervical dysplasia in early clinical trials.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.